We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Altus Pharmaceuticals Reacquires ALTU-238 Global Development and Commercialization Rights
News

Altus Pharmaceuticals Reacquires ALTU-238 Global Development and Commercialization Rights

Altus Pharmaceuticals Reacquires ALTU-238 Global Development and Commercialization Rights
News

Altus Pharmaceuticals Reacquires ALTU-238 Global Development and Commercialization Rights

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Altus Pharmaceuticals Reacquires ALTU-238 Global Development and Commercialization Rights"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Altus Pharmaceuticals Inc. has announced that it has reacquired ALTU-238 development and commercialization rights for North America from Genentech Inc.

Also, the Company announced that the exclusive option granted to Genentech for ALTU-238 development and commercialization outside North America has expired.

ALTU-238 is a subcutaneously administered, once-per-week formulation of human growth hormone, which employs Altus’ proprietary protein crystallization and formulation technology, for patients with growth hormone deficiencies.

“We continue to believe ALTU-238 can provide significant patient benefit with better dosing as a potential once-per-week treatment for growth hormone disorders,” stated Sheldon Berkle, President and CEO of Altus Pharmaceuticals.

“We intend to move this program forward. Our goal is to resume clinical trials by mid-2008 and we expect to provide additional details regarding the clinical development plan to investors during the first quarter. As a unified global program, we also believe significant strategic partnering opportunities exist for ALTU-238.”

Under the revised agreement, Altus regains control of its ALTU-238 assets and Genentech has agreed to provide, for a limited term, supplies of human growth hormone for future clinical development.

In addition, Genentech will provide Altus certain funding to support transition of the program. Upon commercialization, Genentech will be entitled to a nominal royalty on sales of ALTU-238.

Advertisement